Movement Alert｜Kelun-Biotech Falls 3.25% in Regular Trading, Post-Clinical-Milestone Profit-Taking Continues Amid Sector-Wide Weakness

Market Focus07-17

On July 17, Kelun-Biotech declined 3.25% in regular trading, trading at 500.5 HKD/share, with turnover of HKD 197 million.

The decline represents a continuation of profit-taking following the company's announcement on July 15 that its core TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab met the primary endpoint in a Phase III study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC. The stock surged over 11% on that day but has since retreated for two consecutive sessions as investors locked in gains.

The broader biotechnology sector experienced significant selling pressure, amplifying the pullback. Within the sector, AKESO fell 7.81%, 3SBIO fell 6.64%, Remegen fell 6.41%, Innovent Bio fell 2.02%, and BeiGene fell 1.99%. Goldman Sachs had raised its target price to HKD 582.95 on July 16 while maintaining a Buy rating, citing increased probability of success for the Lung06 study from 81% to 90%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143202283?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 09:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143202283","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Kelun-Biotech Falls 3.25% in Regular Trading, Post-Clinical-Milestone Profit-Taking Continues Amid Sector-Wide Weakness","media":"Market Focus","content":"<p><p>On July 17, Kelun-Biotech declined 3.25% in regular trading, trading at 500.5 HKD/share, with turnover of HKD 197 million.</p><p>The decline represents a continuation of profit-taking following the company's announcement on July 15 that its core TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab met the primary endpoint in a Phase III study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC. The stock surged over 11% on that day but has since retreated for two consecutive sessions as investors locked in gains.</p><p>The broader biotechnology sector experienced significant selling pressure, amplifying the pullback. Within the sector, AKESO fell 7.81%, 3SBIO fell 6.64%, Remegen fell 6.41%, Innovent Bio fell 2.02%, and BeiGene fell 1.99%. Goldman Sachs had raised its target price to HKD 582.95 on July 16 while maintaining a Buy rating, citing increased probability of success for the Lung06 study from 81% to 90%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Kelun-Biotech Falls 3.25% in Regular Trading, Post-Clinical-Milestone Profit-Taking Continues Amid Sector-Wide Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Kelun-Biotech Falls 3.25% in Regular Trading, Post-Clinical-Milestone Profit-Taking Continues Amid Sector-Wide Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 09:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, Kelun-Biotech declined 3.25% in regular trading, trading at 500.5 HKD/share, with turnover of HKD 197 million.</p><p>The decline represents a continuation of profit-taking following the company's announcement on July 15 that its core TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab met the primary endpoint in a Phase III study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC. The stock surged over 11% on that day but has since retreated for two consecutive sessions as investors locked in gains.</p><p>The broader biotechnology sector experienced significant selling pressure, amplifying the pullback. Within the sector, AKESO fell 7.81%, 3SBIO fell 6.64%, Remegen fell 6.41%, Innovent Bio fell 2.02%, and BeiGene fell 1.99%. Goldman Sachs had raised its target price to HKD 582.95 on July 16 while maintaining a Buy rating, citing increased probability of success for the Lung06 study from 81% to 90%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1143202283","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143202283","pubTimestamp":1784253435,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, Kelun-Biotech declined 3.25% in regular trading, trading at 500.5 HKD/share, with turnover of HKD 197 million.The decline represents a continuation of profit-taking following the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"走势提醒|科伦生物常规交易下跌3.25%，临床后里程碑获利了结在全行业疲软的情况下仍在继续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On July 17, Kelun-Biotech declined 3.25% in regular trading, trading at 500.5 HKD/share, with turnover of HKD 197 million.The decline represents a continuation of profit-taking following the company's announcement on July 15 that its core TROP2 ADC sacituzumab tirumotecan (sac-TMT) combined with pembrolizumab met the primary endpoint in a Phase III study for first-line treatment of PD-L1-negative advanced non-squamous NSCLC. The stock surged over 11% on that day but has since retreated for two consecutive sessions as investors locked in gains.The broader biotechnology sector experienced significant selling pressure, amplifying the pullback. Within the sector, AKESO fell 7.81%, 3SBIO fell 6.64%, Remegen fell 6.41%, Innovent Bio fell 2.02%, and BeiGene fell 1.99%. Goldman Sachs had raised its target price to HKD 582.95 on July 16 while maintaining a Buy rating, citing increased probability of success for the Lung06 study from 81% to 90%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143202283","isCrawlerRequest":true}